Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Google Scholar through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Dose-Response Met-RANTES Treatment of Experimental Periodontitis: A Narrow Edge between the Disease Severity Attenuation and Infection Control

Full text
Author(s):
Repeke, Carlos Eduardo [1] ; Ferreira, Jr., Samuel Barros [1] ; Vieira, Andreia Espindola [1] ; Silveira, Elcia Maria [1] ; Avila-Campos, Mario Julio [2] ; da Silva, Joao Santana [3] ; Santos, Carlos Ferreira [1] ; Campanelli, Ana Paula [1] ; Favaro Trombone, Ana Paula [4] ; Garlet, Gustavo Pompermaier [1]
Total Authors: 10
Affiliation:
[1] Sao Paulo Univ FOB USP, Sch Dent Bauru, Dept Biol Sci, Sao Paulo - Brazil
[2] Sao Paulo Univ ICB USP, Inst Biomed Sci, Dept Microbiol, Sao Paulo - Brazil
[3] Sao Paulo Univ FMRP USP, Sch Med Ribeirao Preto, Dept Biochem & Immunol, Sao Paulo - Brazil
[4] Inst Lauro Souza Lima, Dept Pathol, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PLoS One; v. 6, n. 7, p. e22526, 2011.
Web of Science Citations: 20
Abstract

Chemokines and chemokine receptors have been implicated in the selective migration of leukocyte subsets to periodontal tissues, which consequently influences the disease outcome. Among these chemoattractants, the chemokines CCL3, CCL4 and CCL5 and its receptors, CCR1 and CCR5, have been associated with increased disease severity in mice and humans. Therefore, in this study we investigated the modulation of experimental periodontitis outcome by the treatment with a specific antagonist of CCR1 and 5 receptors, called met-RANTES. C57Bl/6 mice was orally infected with Aggregatibacter actinomycetemcomitans and treated with 0.05, 0.1, 0.5, 1.5 and 5 mg doses of met-RANTES on alternate days, and evaluated by morphometric, cellular, enzymatic and molecular methods. At 0.5 mg up to 5 mg doses, a strong reduction in the alveolar bone loss and inflammatory cell migration were observed. Interestingly, 5 mg dose treatment resulted in the maximum inhibition of inflammatory cell migration, but resulted in a similar inhibition of bone loss when compared with the lower doses, and also resulted in increased bacterial load and CRP response. When 0.5 and 5 mg therapy regimens were compared it was observed that both therapeutic protocols were able to downregulate the levels of pro-inflammatory, Th1-type and osteoclastogenic cytokines, and CD3+ and F4/80+ cells migration to periodontal tissues, but the high dose modulates host response in a more pronounced and unspecific and excessive way, interfering also with the production of antimicrobial mediators such as MPO, iNOS and IgG, and with GR1+ and CD19+ cells migration. Our results demonstrate a thin line between beneficial immunoregulation and impaired host defense during experimental periodontitis, and the determination of the exact equilibrium point is mandatory for the improvement of immune-targeted therapy of periodontitis. (AU)